Scarica l'app Stockscreener
74.67
5.78%
-4.78
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
ARK Investment Management LLC Decreases Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Amova Asset Management Americas Inc. Decreases Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Legato Capital Management LLC Takes Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
HC Wainwright Analysts Raise Earnings Estimates for IONS - MarketBeat
Ionis Pharmaceuticals (IONS) Receives Price Target Raise to $104 by Leerink Partners | IONS Stock News - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $104.00 at Leerink Partners - MarketBeat
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: A Biotech Powerhouse with 15.60% Upside Potential - DirectorsTalk Interviews
Rafferty Asset Management LLC Decreases Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major PlayersAlnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics - Yahoo Finance UK
FDA Priority Review And 2026 Outlook Might Change The Case For Investing In Ionis (IONS) - Sahm
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Envestnet Asset Management Inc. - MarketBeat
Ionis Priority Review And DAWNZERA Data Reframe Rare Disease Growth Story - Yahoo Finance
Ionis Pharmaceuticals CEO Teases Late-June Olezarsen Launch After FDA Priority Review Acceptance - Yahoo Finance
Olezarsen Priority Review and Expanding Rare Disease Franchise Could Be A Game Changer For Ionis (IONS) - Yahoo Finance
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Artisan Partners Limited Partnership - MarketBeat
Ionis FDA And Phase 3 Updates Reframe Rare Disease Valuation Story - Sahm
Ionis Pharmaceuticals (NASDAQ:IONS) Downgraded by Wall Street Zen to Sell - MarketBeat
Ionis Pharmaceuticals Earnings Call Highlights Surging Momentum - TipRanks
Ionis Pharmaceuticals (NASDAQ:IONS) Given New $100.00 Price Target at Piper Sandler - MarketBeat
Ionis Pharmaceuticals (IONS) Target Price Raised to $100 by Pipe - GuruFocus
Ionis presents new data on hereditary angioedema drug at AAAAI By Investing.com - Investing.com India
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amarin (AMRN), Ionis Pharmaceuticals (IONS) and Repligen (RGEN) - The Globe and Mail
Ionis presents new data on hereditary angioedema drug at AAAAI - Investing.com
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting - Business Wire
TD Asset Management Inc Sells 144,418 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Dana Investment Advisors Inc. Acquires Shares of 18,818 Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Ionis Pharmaceuticals (IONS) and Axsome Therapeutics (AXSM) - The Globe and Mail
Ionis Pharmaceuticals Stock: Digesting Recent Events (NASDAQ:IONS) - Seeking Alpha
Decoding Ionis Pharmaceuticals Inc (IONS): A Strategic SWOT Insi - GuruFocus
Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90 - Bitget
Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook - The Globe and Mail
Olezarsen sNDA accepted by the FDA for Priority Review - marketscreener.com
IONS: Priority review for olezarsen accelerates launch plans amid robust pipeline and commercial momentum - TradingView
IONS: Priority review for olezarsen and robust pipeline set stage for major growth and global expansion - TradingView
FDA Grants Priority Review to Ionis Pharmaceuticals' Olezarsen A - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $77.00 - MarketBeat
Ionis Pharmaceuticals (IONS) Analyst Rating Update: Stifel Maint - GuruFocus
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2025 Earnings Call Transcript - Insider Monkey
Needham Raises Ionis Pharmaceuticals (IONS) Price Target to $103 - GuruFocus
6 Analysts Have This To Say About Ionis Pharmaceuticals - Benzinga
Drug cutting pancreatitis attacks 85% gets speedy FDA review - Stock Titan
Ionis Pharmaceuticals Q4 Loss Of US$229 Million Tests Bullish Profitability Narrative - Sahm
Needham Maintains Buy on Ionis Pharmaceuticals (IONS) Feb 25, 2026 - Meyka
Morgan Stanley raises Ionis Pharmaceuticals price target on strong execution - Investing.com
Ionis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) Q4 2025 Earnings Call Highlight - GuruFocus
Ionis Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
RBC Capital reiterates Ionis Pharmaceuticals stock rating at Outperform By Investing.com - Investing.com South Africa
RBC Capital reiterates Ionis Pharmaceuticals stock rating at Outperform - Investing.com Australia
Earnings call transcript: Ionis Pharmaceuticals Q4 2025 misses EPS forecast, stock drops - Investing.com Australia
Ionis outlines >$2B peak sales target for olezarsen as new launches and pipeline catalysts drive 2026 outlook - MSN
Ionis Pharmaceuticals Reports Better-Than-Expected Q4 Results - Intellectia AI
Ionis Guides Below 2026 Sales Views Despite Strong Growth From Lead DrugIonis Pharmaceuticals (NASDAQ:IONS) - Benzinga
Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap Down Following Weak Earnings - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Posts Quarterly Earnings Results, Misses Expectations By $0.18 EPS - MarketBeat
Ionis YE 2025 slides: commercial revenue surges 49%, stock falls on EPS miss - Investing.com
Ionis Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:IONS) 2026-02-25 - Seeking Alpha
(IONS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2026 - marketscreener.com
Ionis (IONS) Projects Significant Revenue Growth by 2026 - GuruFocus
Ionis (IONS) Exceeds Revenue Expectations and Plans Major Launches in 2026 - GuruFocus
Ionis Pharmaceuticals: Fourth Quarter Earnings Overview - Bitget
Ionis Pharmaceuticals' Q4 Net Loss Widens, Revenue Declines; 2026 Revenue Outlook Issued - marketscreener.com
Earnings Flash (IONS) Ionis Pharmaceuticals Posts Q4 Revenue $203M, vs. FactSet Est of $157.7M - marketscreener.com
3.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):